Ewing Sarcoma – Comprehensive Study Notes

Introduction & Epidemiology

• Definition: Rare malignant bone/soft-tissue tumour that predominantly affects children & young adults.
• Rank: Second most common primary bone cancer in paediatrics after osteosarcoma.
• Age distribution: Peak incidence between $10{-}20$ yr; uncommon <$5$ yr & >$30$ yr.
• Sex ratio: Slight male predominance (≈$1.5:1$ M : F).
• Ethnic/geographical variation:
  • Highest incidence in Caucasians; markedly lower in African-Americans & almost absent in East-Asian populations ⇒ suggests genetic predisposition.
• Incidence rate: Global annual incidence ≈$1{-}3$ cases / $10^{6}$ pop.; USA ≈$200{-}300$ new diagnoses / yr.
• Birth & environmental factors:
  • Possible associations with higher birth-weight, prenatal factors; no consistent environmental carcinogen identified.

Genetic Changes – EWSR1 Fusions

• Tumour spectrum: Classic Ewing sarcoma, Askin’s tumour (chest wall), primitive neuro-ectodermal tumour (PNET).
• Presumed cell of origin: Mesenchymal progenitor / stem cell of bone or soft-tissue.
• Hallmark alteration: Chromosomal translocations creating fusion oncogenes between EWSR1 (RNA-binding protein) & ETS-family TFs.
  • Dominant fusion: $\text{EWSR1::FLI1}$ (≈$85\%$) via $t(11;22)(q24;q12)$.
  • Alternatives: $\text{EWSR1::ERG}$ (≈$10\%$); rare fusions with $ETV1$, $ETV4$, $FEV$, etc.
• Normal gene functions:
  • $\text{EWSR1}$ – RNA processing, transcription modulation, DNA-repair scaffolding.
  • $\text{FLI1}$ – Regulates proliferation, differentiation, survival.
• Oncogenic fusion protein (EWSR1-FLI1):
  • Acts as aberrant TF binding GGAA microsatellites ⇒ de-novo ("neo") enhancers; rewires chromatin landscape.
  • Activates oncogenes (e.g., $NKX2\text{-}2$, $CCND1$), represses tumour suppressors (e.g., $TP53$ downstream pathways).
  • Alters RNA-splicing, mRNA stability, non-coding RNA expression (represses $\text{miR!-145}$).
  • Promotes genomic instability by disrupting DNA-repair machinery.
• Protein biophysics:
  • EWSR1 N-terminus is intrinsically disordered → phase-separation & nuclear condensate formation.
  • Post-translational regulation via phosphorylation, ubiquitination, acetylation; key cofactors $\text{RHA}$, $\text{PARP-1}$, BRD proteins.
• Diagnostics:
  • Gold standard – molecular detection of EWSR1 rearrangement (RT-PCR, FISH, NGS).
  • IHC: Strong membranous $\text{CD99}$, nuclear $\text{FLI1}$; supportive but not specific.

Therapy Options & Current Challenges

• Standard-of-care: Multi-agent cytotoxic chemotherapy (doxorubicin, vincristine, cyclophosphamide, etoposide, ifosfamide) + surgery ± radiotherapy.
  • Five-year OS improved since $1980$s but plateaued, especially in metastatic / relapsed disease.
  • Significant acute & long-term toxicities (cardiotoxicity, fertility loss, growth disturbance).
• Urgent needs: Increase survival; mitigate toxicity; overcome resistance.

Epigenetic-based therapies

• Rationale: Fusion protein operates via chromatin remodelling → druggable epigenetic cofactors.
• Agents under investigation:
  • $\text{HDAC}$ inhibitors, $\text{LSD1}$ inhibitors, $\text{EZH2}$ inhibitors, BET bromodomain degraders.
• Pre-clinical potency high; monotherapy clinical responses modest.
• Current focus: 2nd-generation, higher-specificity compounds; PROTAC-mediated degradation vs catalytic inhibition; rational combinations (chemo, immune-modulators).

Immunotherapy landscape

• Tumour described as "immune-cold" (low TILs, low PD-L1).
• Strategies:
  • Combine epigenetic priming or cytotoxics to increase neo-antigen presentation.
  • Modulate TME: vasculature normalisation, alleviating hypoxia.
  • CRISPR screens to unveil synthetic-lethal immune checkpoints.

Nanomedicine / Drug-delivery

• Nanoparticles (NPs) enhance tumour-specific delivery, allow re-use of highly potent yet previously discarded drugs.
• Potential to reduce systemic exposure & circumvent MDR pumps.

Tumour heterogeneity & modelling

• Inter- & intra-patient genetic / phenotypic diversity challenges treatment prediction.
• Traditional cell-line & murine xenografts under-represent heterogeneity; patient-derived organoids & CAF-like cell co-cultures emerging.

Biomarkers & precision medicine

• Need for universal surface antigens to enable antibody-drug conjugates / CAR-T.
• Molecular biomarkers (fusion type, gene expression signatures, circulating DNA) for risk stratification & adaptive trial design.

Birth-Characteristics Case–Control Study (California $1978{-}2015$)

• Cohort: $556$ Ewing sarcoma cases vs $27{,}800$ matched controls (year-of-birth matched).
• Method: Multivariable logistic regression adjusting for sex, SES, parental age.
• Race/ethnicity odds ratios (vs non-Hispanic White):
  • Black: $\approx 93\%$ lower risk (OR $0.07$).
  • Asian: $\approx 43\%$ lower risk (OR $0.57$).
  • Hispanic: $\approx 27\%$ lower risk (OR $0.73$).
  • Disparities accentuated in metastatic subset.
• Birth-weight: Risk ↑ $9\%$ per $500\,\text{g}$ increment.
• Familial clustering: No significant excess sibling / parent–child aggregation detected ⇒ large germline predisposition unlikely.

Biological Uniqueness

• Single dominant driver: $\text{EWSR1–FLI1}$ fusion; mutational burden otherwise low ⇒ genomic stability.
• Lineage ambiguity: Displays both mesenchymal & neural markers (e.g., $\text{CD99}$, $\text{NSE}$) – blurs conventional sarcoma taxonomy.
• Epigenetic re-programming: Fusion hijacks GGAA microsatellite density to pioneer novel super-enhancers → aberrant transcriptome.
• Immune phenotype: "Cold" microenvironment with low antigenicity & immunosuppressive stroma (CAF-like ES cells remodel ECM & signalling).
• Clinical behaviour: Highly aggressive; early haematogenous metastasis (lungs, bone-marrow).

Ethical / Practical Considerations

• Balancing cure vs toxicity in children: Long-term quality-of-life, fertility, secondary malignancies.
• Access disparities: Lower incidence in certain ethnicities may impede clinical-trial enrolment → potential biases in therapeutic development.
• Genomic testing equity: Universal access to fusion testing needed for precise diagnosis & trial eligibility.

Cross-links to Broader Oncology Concepts

• ETS-fusion paradigm parallels prostate cancer (TMPRSS2-ERG) & AML (ETO-RUNX1) → shared transcriptional rewiring mechanisms.
• Phase-separation & condensate biology gaining prominence across oncogenic fusions (e.g., NUP98 fusions, FUS-DDIT3 in myxoid liposarcoma).
• Low-mutational cancers challenge checkpoint-blockade, underscoring need for alternative immunologic approaches (vaccines, engineered TCRs).

Key Numerical Summary

• Incidence: $1{-}3$/$10^{6}$ annually; US $200{-}300$ cases/yr.
• Age peak: $10{-}20$ yr.
• Male:female $1.5:1$.
• Fusion prevalence: $\text{EWSR1::FLI1}$ $85\%$; $\text{EWSR1::ERG}$ $10\%$.
• Birth-weight risk increment: $9\%$ per $500\,\text{g}$.

Bibliography (for further reading)

• Li M & Chen CW (2022) "Epigenetic and Transcriptional Signalling in Ewing Sarcoma" Biomedicines $10(6):1325$.
• Nacev BA et al. (2020) "Epigenomics of Sarcoma" Nat Rev Cancer $20:608–623$.
• Sánchez-Molina S et al. (2022) "Ewing Sarcoma Meets Epigenetics, Immunology & Nanomedicine" Cancers $14:5473$.
• Wiemels JL et al. (2023) "Birth Characteristics & Risk of Ewing Sarcoma" Cancer Causes Control $34:837–843$.
• Wrenn ED et al. (2023) "CAF-like Tumor Cells Remodel ES TME" Clin Cancer Res $29:5140–5154$.
• Yu L, Davis IJ, Liu P (2023) "Regulation of EWSR1-FLI1" Cancers $15:382$.